Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase Ib Trial of Tegavivint in Patients With Relapsed/Refractory C-MYC Overexpressing Large B-Cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05755087
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:19.960560+00:00
Published At
2026-02-27T00:00:00+00:00
Record Updated At
2026-02-27
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-27"
protocolSection.identificationModule.nctId
"NCT05755087"
protocolSection.identificationModule.officialTitle
"Phase Ib Trial of Tegavivint in Patients With Relapsed/Refractory C-MYC Overexpressing Large B-Cell Lymphoma"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type (protocolSection.conditionsModule.conditions)
  • Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type (protocolSection.conditionsModule.conditions)
  • Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
  • Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
  • Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type (protocolSection.conditionsModule.conditions)
  • Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type (protocolSection.conditionsModule.conditions)
  • Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
  • Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
  • Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.